Dr. Yang is the principal investigator on four major (R01) National Institutes of Health grants:
Alpha–1 AD Carriers and Lung Cancer Risk
The aim of this case–control study is to test the hypothesis that α1AD carriers are at an increased risk of developing lung cancer. This study will allow us to evaluate the roles of:
- A common gene that is associated with lung tissue damage,
- Tobacco smoke (carcinogen) exposure, and
- COPD that shares common risk factors with lung cancer and often occurs before the onset of lung cancer.
Results from this study will lead to further understanding of the biologic basis of lung cancer development and progression, may uncover an additional marker for identifying high–risk individuals, and could provide additional impetus for targeted behavior modification, chemo–prevention, and gene therapy programs.
Genetic Determinants of Lung Cancer Survival
From this study, we will confirm or refute whether genotypes indicative of deficient or absent enzyme activities in the GSH system predict better short–term survival. Our results may suggest a new direction to enhance lung cancer chemotherapy by suppressing or depleting the relevant enzymes. Our results may also assist clinicians in planning patient–specific therapy and more accurately predicting prognosis. Through this project, we will establish a valuable data resource and an infrastructure to study promising biological markers for short– and long–term prognosis of lung cancer patients.
Genetic Epidemiology of Lung Cancer
The objective of this study is to locate lung cancer gene(s) in human genome using families with four or more lung cancer patients.
Health and Quality of Life among Long–Term Lung Cancer Survivors
This study enrolls and follows up more–than–expected five–year lung cancer survivors to get a profile on patient’s well being and to screen for some positive/negative factors that may affect the patient’s clinical long–term prognosis.
Learn more by reading brochures about our primary studies: